Please use this link to access this publication. Abstract: Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD). Objective: To measure efficacy and safety of medical cannabis oil…
Condition: Alzheimer’s Dementia
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
Abstract The discovery of endocannabinoid’s role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The…
Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study
Please use this link to access this publication. Abstract Aim: Currently, there exist no curative treatments for neurodegenerative disorders. Recently, there has been a resurgence of interest in the use of…
Feline cognitive dysfunction as a model for Alzheimer’s disease in the research of CBD as a potential treatment—a narrative review
Abstract With the improvement in modern medicine, the world’s human and feline (Felis catus, the domestic cat) population is aging. As the population grows older, there is an increase of…
Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice
Please use this link to access this publication. Abstract: Alzheimer’s disease (AD) is characterized by progressive cognitive decline and pathologically by the accumulation of amyloid-β (Aβ) and tau hyperphosphorylation causing neurodegeneration…
Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer’s Dementia
Please use this link to access this publication. Abstract Introduction Alzheimer’s disease (AD) is a debilitating neurodegenerative disease accounting for 60-80% of dementia cases worldwide. In the United States alone,…
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (THC-AD)
Abstract Background Although agitation in Alzheimer’s Disease (Agit-AD) is a common and troubling neuropsychiatric syndrome, behavioral interventions lack consistent efficacy and there are no FDA-approved medications. Neurobiological mechanisms that contribute…
The Role of Cannabidiol in Neurological Disorders
Abstract Cannabis has been used for both recreational and medicinal purposes for more than 4 millennia. Cannabis has been studied in various medical disorders including neurological disorders. There are well-known…
An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model
Abstract Alzheimer’s disease (AD) is the most common form of dementia, but there is still no available treatment. Δ9-tetrahydrocannabinol (THC) is emerging as a promising therapeutic agent. Using THC in…
Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer’s Disease (THC-AD)
Please use this link to access this publication. Abstract Introduction Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease of aging (70%). Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to…